The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast

被引:22
作者
de Roos, M. A. J.
van der Vegt, B.
Peterse, J. L.
Patriarca, C.
de Vries, J.
de Bock, G. H.
Wesseling, J.
机构
[1] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Pathol, NL-10066 CX Amsterdam, Netherlands
[2] Univ Groningen, Med Ctr, Dept Surg Oncol, Groningen, Netherlands
[3] Univ Groningen, Med Ctr, Dept Pathol, Groningen, Netherlands
[4] Azienda Osped Melegnano, Dept Pathol, Milan, Italy
[5] Univ Groningen, Med Ctr, Dept Epidemiol, Groningen, Netherlands
关键词
ductal carcinoma in situ; EMA; immunohistochemistry; local recurrence; MUC1; tissue microarray;
D O I
10.1111/j.1365-2559.2007.02754.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims: To classify MUC1 according to five predefined expression patterns in ductal carcinoma in situ (DCIS) and related clinicopathological parameters, coexpression of other biological markers and prognosis. Methods and results: With a manual tissue arrayer, 92% (n = 80) of the 87 DCIS samples were successfully targeted. Immunohistochemistry was carried out for MUC1, oestrogen receptor (ER), progesterone receptor (PR), Her2/Neu, p53 and cyclin D1. Entire membrane expression was related to Her2/neu negativity (P =0.042). Apical membrane expression was associated with low grade (P = 0.027), Her2/neu negativity (P = 0.014) and PR positivity (P = 0.005). Focal cytoplasmic expression was related to high grade (P = 0.006). Diffuse cytoplasmic expression was associated with high grade (P = 0.004), large tumour size (P = 0.046), Her2/neu positivity (P = 0.042) and cyclin D1 positivity (P = 0.002). On the basis of these analyses the four patterns were reclassified as membranous or cytoplasmic expression. On multivariate analysis, cytoplasmic MUC1 expression (hazard ratio 8.5, 95% confidence interval 1.0, 73.0; P = 0.04) was the only independent predictor of local recurrence. Conclusions: Four patterns of MUC1 expression are recognized in DCIS that suggest a relationship to functional differentiation and can be simplified into two types that are clinically relevant and could therefore be helpful in the distinction between different subgroups of DCIS.
引用
收藏
页码:227 / 238
页数:12
相关论文
共 34 条
[1]   MUC1 and nuclear β-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis [J].
Baldus, SE ;
Mönig, SP ;
Huxel, S ;
Landsberg, S ;
Hanisch, FG ;
Engelmann, K ;
Schneider, PM ;
Thiele, J ;
Hölscher, AH ;
Dienes, HP .
CLINICAL CANCER RESEARCH, 2004, 10 (08) :2790-2796
[2]   Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: Ten-Year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 - A study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group [J].
Bijker, Nina ;
Meijnen, Philip ;
Peterse, Johannes L. ;
Bogaerts, Jan ;
Van Hoorebeeck, Irene ;
Julien, Jean-Pierre ;
Gennaro, Massimiliano ;
Rouanet, Philippe ;
Avril, Antoine ;
Fentiman, Ian S. ;
Bartelink, Harry ;
Rutgers, Emiel J. Th. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (21) :3381-3387
[3]   Patterns of MUC1 tissue expression defined by an anti-MUC1 cytoplasmic tail monoclonal antibody in breast cancer [J].
Croce, MV ;
Isla-Larrain, MT ;
Rua, CE ;
Rabassa, ME ;
Gendler, SJ ;
Segal-Eiras, A .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2003, 51 (06) :781-788
[4]   Correlation between imaging and pathology in ductal carcinoma in situ of the breast [J].
de Roos M.A.J. ;
Pijnappel R.M. ;
Post W.J. ;
de Vries J. ;
Baas P.C. ;
Groote L.D. .
World Journal of Surgical Oncology, 2 (1)
[5]  
Diaz L K, 2001, Breast J, V7, P40, DOI 10.1046/j.1524-4741.2001.007001040.x
[6]   Immunohistochemical study of p185 HER2 and DF3 in primary breast cancer and correlation with CA-15-3 serum tumor marker [J].
Dimas, C ;
Frangos-Plemenos, M ;
Kouskouni, E ;
Kondis-Pafitis, A .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2002, 12 (01) :74-79
[7]   MUC1 expression in primary breast cancer: the effect of tamoxifen treatment [J].
Hanson, JM ;
Browell, DA ;
Cunliffe, WJ ;
Varma, J ;
Allen, A ;
Hemming, D ;
Shenton, BK ;
Young, JR ;
Higgs, MJ ;
Brotherick, I ;
Pearson, JP .
BREAST CANCER RESEARCH AND TREATMENT, 2001, 67 (03) :215-222
[8]   PREDICTION OF PROGNOSIS IN PRIMARY BREAST-CANCER BY DETECTION OF A HIGH-MOLECULAR-WEIGHT MUCIN-LIKE ANTIGEN USING MONOCLONAL-ANTIBODIES DF3, F36/22, AND CU18 - A CANCER AND LEUKEMIA GROUP-B STUDY [J].
HAYES, DF ;
MESATEJADA, R ;
PAPSIDERO, LD ;
CROGHAN, GA ;
KORZUN, AH ;
NORTON, L ;
WOOD, W ;
STRAUCHEN, JA ;
GRIMES, M ;
WEISS, RB ;
REE, HJ ;
THOR, AD ;
KOERNER, FC ;
RICE, MA ;
BARCOS, M ;
KUFE, DW .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (07) :1113-1123
[9]   Monoclonal antibodies against the nonmucin domain of institute MUC1/episialin [J].
Hilkens, J ;
Boer, M .
TUMOR BIOLOGY, 1998, 19 :67-70
[10]  
HILKENS J, 1995, BIOCH CELL MEMBRANES, P259